| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
154,660,000 |
| Market
Cap: |
184.05(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.429 - $1.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
39,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$11,326 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
| Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
| Total People Sold |
0 |
4 |
5 |
6 |
| Total Sell Transactions |
0 |
16 |
19 |
41 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Norry Elliot |
Chief Medical OfficerOfficer |
• – – |
2020-01-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,679 |
|
47% |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2020-01-06 |
4 |
S |
$1.20 |
$4,477 |
D/D |
(3,731) |
5,632 |
|
-275% |
|
| Rawcliffe Adrian |
Chief Executive Officer |
• • – |
2020-01-06 |
4 |
S |
$1.20 |
$7,080 |
D/D |
(5,900) |
5,804 |
|
-275% |
|
| Lunger John |
Chief Patient Supply Officer |
• – – |
2020-01-06 |
4 |
S |
$1.20 |
$1,378 |
D/D |
(1,148) |
1,677 |
|
-275% |
|
| Amado Rafael |
President, R&D |
• – – |
2019-08-06 |
4 |
S |
$2.06 |
$22,749 |
D/D |
(11,043) |
17,237 |
|
- |
|
| Lunger John |
Chief Patient Supply OfficerOf |
• – – |
2019-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,806 |
|
- |
|
| Noble James |
Chief Executive Officer |
• • – |
2019-05-16 |
4 |
OE |
$0.14 |
$253,553 |
D/D |
1,773,100 |
1,773,100 |
|
- |
|
| Rawcliffe Adrian |
Chief Financial Officer |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$16,559 |
D/D |
(3,084) |
3,318 |
|
- |
|
| Binder-Scholl Gwendolyn Knowlton |
Chief Technology Officer |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$8,129 |
D/D |
(1,514) |
2,487 |
|
- |
|
| Bertrand William C Jr |
Chief Operating Officer |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$12,194 |
D/D |
(2,271) |
3,731 |
|
- |
|
| Amado Rafael |
President, R & D |
• – – |
2019-01-14 |
4 |
S |
$5.37 |
$16,259 |
D/D |
(3,028) |
4,974 |
|
- |
|
| Alleva Lawrence M |
Director |
– • – |
2018-12-17 |
4 |
B |
$0.84 |
$39,715 |
I/I |
47,280 |
47,280 |
2.1 |
- |
|
| Binder-Scholl Gwendolyn Knowlton |
Chief Technology Officer |
• – – |
2018-10-01 |
4 |
AS |
$13.79 |
$344,750 |
D/D |
(25,000) |
0 |
|
- |
|
| Barris Peter J |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Baskett Forest |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Nea 14 Gp, Ltd |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$5,000,100 |
D/D |
3,000,000 |
82,978,668 |
2.45 |
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Mott David M |
Director |
– • • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
2.25 |
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Behbahani Ali |
Director |
– • – |
2018-09-07 |
4 |
B |
$1.67 |
$20,000,400 |
I/I |
12,000,000 |
12,000,000 |
2.1 |
- |
|
| Kerins Patrick J |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$5,000,100 |
I/I |
3,000,000 |
82,978,668 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Barrett M James |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$5,000,100 |
I/I |
3,000,000 |
82,978,668 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2018-09-07 |
4 |
B |
$1.67 |
$25,000,500 |
I/I |
15,000,000 |
12,000,000 |
1.5 |
- |
|
| Binder-Scholl Gwendolyn Knowlton |
Chief Technology Officer |
• – – |
2018-08-29 |
4 |
AS |
$10.25 |
$256,250 |
D/D |
(25,000) |
0 |
|
- |
|
234 Records found
|
|
Page 5 of 10 |
|
|
